Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(0.60)
# 4,093
Out of 5,182 analysts
9
Total ratings
42.86%
Success rate
-16.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $1.70 | +370.59% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $27.80 | -10.07% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $0.33 | +1,416.53% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $62.13 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $3.48 | +532.18% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $40.70 | +180.10% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $19.21 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.70
Upside: +370.59%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $27.80
Upside: -10.07%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $0.33
Upside: +1,416.53%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $62.13
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $3.48
Upside: +532.18%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $40.70
Upside: +180.10%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $19.21
Upside: -